Coronavirus (COVID-19) Current Therapy Market 2025

Coronavirus (COVID-19) Current Therapy Market Definition

Coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts. The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.

Coronavirus (COVID-19) Current Therapy Market Segmentation

The coronavirus (COVID-19) current therapy market is segmented by drug type, by route of administration and by end-user. By Drug Type – The coronavirus (COVID-19) current therapy market is segmented by drug type into: a) Antivirals b) Monoclonal Antibodies (Mabs) c) Corticosteroid d) Supplements e) Antimalarial a) Interferons And Interleukin Inhibitors b) Other Anti Infections c) Others Drug Types The antiviral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug type, accounting for 29.54% or $2,766.87 million of the total in 2024. Going forward, the mabs segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by drug type, at a CAGR of -40.94% during 2024-2029. By Route Of Administration – The coronavirus (COVID-19) current therapy market is segmented by route of administration into: a) Oral b) Intravenous The oral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by route of administration, accounting for 64.28% or $6,021.45 million of the total in 2024. Going forward, the intravenous segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by route of administration, at a CAGR of -40.16% during 2024-2029. By End-User – The coronavirus (COVID-19) current therapy market is segmented by end-user into: a) Hospitals b) Clinics c) Home Care d) Other End-Users The hospitals market was the largest segment of the COVID-19 current therapy market segmented by end-user, accounting for 57.49% or $5,385.60 million of the total in 2024. Going forward, the home care segment is expected to be the fastest growing segment in the COVID-19 current therapy market segmented by end-user, at a CAGR of -42.36% during 2024-2029. By Geography - The coronavirus (COVID-19) current therapy market is segmented by geography into: o Asia Pacific • China • India • Japan • Australia • Indonesia • South Korea o North America • USA • Canada o South America • Brazil o Western Europe • France • Germany • UK • Italy • Spain o Eastern Europe • Russia o Middle East
o Africa North America was the largest region in the coronavirus (COVID-19) current therapy market, accounting for 54.44% or $5,099.38 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the coronavirus (COVID-19) current therapy market will be North America and Western Europe where growth will be at CAGRs of -40.16% and -42.83% respectively. These will be followed by Asia-Pacific and Eastern Europe where the markets are expected to grow at CAGRs of -50.58% and -53.28% respectively.

Coronavirus (COVID-19) Current Therapy Market Drivers

The key drivers of the coronavirus (COVID-19) current therapy market include: Rising Prevalence Of Chronic Diseases The rising prevalence of chronic diseases is expected to propel the growth of the coronavirus (COVID-19) current therapy market during the forecast period. Chronic conditions such as diabetes, cardiovascular diseases and respiratory disorders compromise the immune system, increasing the risk of severe COVID-19 outcomes. As the prevalence of these chronic conditions continues to rise, there is a growing need for effective therapies that can address the unique challenges faced by at-risk populations. For instance, according to the National Library of Medicine, a US-based agency, the number of people in the USA aged 50 and older who have at least one chronic condition will increase to 142.66 million by 2050. Additionally, as of 2023, according to the World Health Organization, non-communicable diseases (NCDs) or chronic diseases account for 41 million deaths every year globally, which is 74% of all deaths. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases will drive the growth of the coronavirus (COVID-19) current therapy market.

Coronavirus (COVID-19) Current Therapy Market Restraints

The key restraints on the coronavirus (COVID-19) current therapy market include: High Cost Of Therapies High cost of therapies is expected to restrain the growth of the coronavirus (COVID-19) current therapy market during the forecast period. Advanced therapies, including monoclonal antibodies, gene therapies and personalized medicine, are often associated with high production costs, rigorous clinical trials and complex manufacturing processes. Monoclonal antibodies (mAbs) are one of the most powerful tools in modern medicine, offering a highly specific and effective treatment for a range of conditions from infectious diseases like COVID-19 to chronic illnesses such as cancer and autoimmune disorders. For instance, in November 2024, a single course of monoclonal antibody therapy can cost between $1,500 and $2,500, making widespread distribution challenging. Therefore, the high cost of therapies is expected to hamper the growth of the coronavirus (COVID-19) current therapy market.

Coronavirus (COVID-19) Current Therapy Market Trends

Major trends shaping the coronavirus (COVID-19) current therapy market include: Strategic Investments Driving COVID-19 Therapy Market Growth Major companies operating in the coronavirus (COVID-19) current therapy market are focusing on strategic investments to accelerate the development of effective therapies and expand clinical research. Strategic investments drive the growth of the coronavirus (COVID-19) current therapy market by boosting funding for research and development, allowing manufacturers to develop more efficient and advanced antiviral therapies. For example, in August 2024, Apple Tree Partners (ATP), a US-based life sciences venture capital firm announced an investment of $55 million in a biotechnology startup Red Queen Therapeutics Inc., specializing in the development of antiviral therapies designed to target multiple virus families. This strategic investment underscores ATP's dedication to fostering innovation and advancing cutting-edge therapeutic solutions within the life sciences industry. Red Queen leverages a cutting-edge stapled lipopeptide platform to enable the swift development of antiviral therapies. This innovative technology targets the inhibition of viral fusion, a critical stage in the infection process. The company achieved a significant milestone by completing a successful Phase 1 clinical trial for its lead candidate, RQ-01 (a novel antiviral therapeutic), designed to combat COVID-19. Advancements In Antiviral Drug Development For COVID-19 Treatment Companies operating in the coronavirus (COVID-19) current therapy market are focusing on developing antiviral drugs to address the evolving needs of patients and enhance therapeutic outcomes. Antiviral drugs are specialized treatments developed to combat viral infections by disrupting the replication and spread of viruses within the body. Antiviral drugs are uniquely tailored to target viruses. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for the oral antiviral treatment, PAXLOVID. This drug is used for the treatment of adults with mild-to-moderate COVID-19 who are at high risk of severe outcomes, including hospitalization or death. Clinical studies have shown that PAXLOVID significantly reduces the risk of hospitalization or death by approximately 86% when administered within five days of symptom onset.

Opportunities And Recommendations In The Coronavirus (COVID-19) Current Therapy Market

Opportunities – The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by drug type will arise in the supplements segment, which will gain $-80.63 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy market segmented by route of administration will arise in the intravenous segment, which will gain $-3,089.50 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by end-user will arise in the other end-users segment, which will gain $-827.84 million of global annual sales by 2029. The coronavirus (COVID-19) current therapy market size will gain the most in Indonesia at $-32.30 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the COVID-19 current therapy companies to focus on strategic investments and R&D for growth, focus on developing targeted antiviral therapies, focus on innovating digital platforms for enhanced patient care, focus on the "others" anti-infections segment, focus on the oral segment, expand in emerging markets, focus on expanding distribution channels to enhance accessibility, focus on strategic pricing to maximize market penetration, focus on building trust and credibility for COVID-19 therapy companies, focus on strategic partnerships with healthcare providers and insurers to boost product adoption and focus on the home care market.